TF and neoplasm: In 2008, Shoji et al (2008) reported the use of an active site-inactivated recombinant human fVIIa (FFRck–fVIIa) as a carrier for the targeted delivery of a potent synthetic curcumin analogue (EF24) to TF-expressing tumour-associated VECs and tumours.